Clinical and pathological disappearance of peritoneal dissemination in a patient with advanced gastric cancer receiving chemotherapy with S-1 and low-dose cisplatin

被引:4
|
作者
Akatsu Y. [1 ]
Saikawa Y. [1 ]
Kubota T. [1 ]
Yoshida M. [1 ]
Furukawa T. [1 ]
Otani Y. [1 ]
Kumai K. [2 ]
Kitajima M. [1 ]
机构
[1] Department of Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582
[2] Ctr. for Diagn./Therapeut. Endoscopy, Keio University School of Medicine, Tokyo
关键词
Cisplatin; Gastric cancer; Peritoneal dissemination; S-1;
D O I
10.1007/s10120-004-0281-8
中图分类号
学科分类号
摘要
A 54-year-old woman with severe abdominal distention suffered from massive ascites. Cytological examination revealed adenocareinoma cells, leading to a diagnosis of peritonitis carcinomatosa. Gastrointestinal fiberseopy (GIF) resulted in a histological diagnosis of type 4 advanced gastric cancer with signet-ring cell carcinoma. The clinical diagnosis was confirmed to be cT3(SE)cN1cM0cH0cP1, cStage IV gastric cancer, type 4, according to the Japanese classification of gastric carcinoma. The patient was treated with S-1 and low-dose cisplatin (CDDP) in order to alleviate the critical state of the disease. After the third cycle of the regimen, the clinical response of P1 was classified as a partial response (PR) according to the World Health Organization (WHO) criteria. The patient's appetite loss and abdominal discomfort were markedly alleviated. The patient experienced grade 2 leukocytopenia throughout the regimen. Surgery was performed. Ascites and peritoneal disseminated lesions were not observed, and cytological examination of the peritoneal washes was negative. Total gastrectomy with D1 lymph node dissection was performed, and the surgical diagnosis was sT3(SE)sN0sM0sH0sP0; sStage II Microscopically, viable cancer cells were found to be scattered throughout the subserosal-serosal layers in the resected stomach. All of the samples from lesions that were potentially cancers involving peritoneal dissemination were diagnosed as fibrous scar tissues without any viable cancer cells. The patient is alive without recurrence at 10 months after surgery and 14 months after the initial chemotherapy. Thus, systemic chemotherapy with S-1/low-dose CDDP achieved desirable control of peritoneal disseminated cells, as assessed microscopically, suggesting that the regimen may be an effective strategy for the treatment of advanced gastric cancer with peritonitis carcinomatosa.
引用
收藏
页码:128 / 133
页数:5
相关论文
共 50 条
  • [21] Comparison of S-1 and cisplatin combination versus S-1 adjuvant chemotherapy for advanced gastric cancer
    Kim, Hyo Song
    Jeung, Hei-Cheul
    Jung, Minkyu
    Kim, Hye Ryun
    Ahn, Ji Yeong
    Kim, Hyoung-Il
    Cheong, Jae-Ho
    Hyung, Woo Jin
    Noh, Sung Hoon
    Chung, Hyun Cheol
    Rha, Sun Young
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer
    Tamura, Shigeyuki
    Miki, Hirofumi
    Nakata, Ken
    Takiuchi, Daisuke
    Okada, Kaoru
    Nakahira, Shin
    Okamura, Shu
    Sugimoto, Keishi
    Tomita, Naohiro
    Takatsuka, Yuichi
    GASTRIC CANCER, 2007, 10 (04) : 251 - 255
  • [23] Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer
    Shigeyuki Tamura
    Hirofumi Miki
    Ken Nakata
    Daisuke Takiuchi
    Kaoru Okada
    Shin Nakahira
    Shu Okamura
    Keishi Sugimoto
    Naohiro Tomita
    Yuichi Takatsuka
    Gastric Cancer, 2007, 10 : 251 - 255
  • [24] Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer
    Hideo Baba
    Manabu Yamamoto
    Kazuya Endo
    Yasuharu Ikeda
    Yasushi Toh
    Shunji Kohnoe
    Takeshi Okamura
    Gastric Cancer, 2003, 6 (Suppl 1) : 45 - 49
  • [25] Combination chemotherapy of S-1 and paclitaxel or cisplatin for advanced or recurrent gastric cancer
    Aoki, T.
    Sumi, T.
    Takagi, M.
    Kato, F.
    Suzuki, Y.
    Yasude, Y.
    Yoneda, K.
    Ogata, T.
    ANNALS OF ONCOLOGY, 2006, 17 : 91 - 91
  • [26] Moderate neutropenia with S-1 plus low-dose cisplatin may predict a more favourable prognosis in advanced gastric cancer
    Nakata, B.
    Tsuji, A.
    Mitachi, Y.
    Yamamitsu, S.
    Hirata, K.
    Takeuchi, T.
    Shirasaka, T.
    Hirakawa, K.
    CLINICAL ONCOLOGY, 2006, 18 (09) : 678 - 683
  • [27] Clinical Experience with Chemoradiotherapy Comprising S-1 Plus Low-dose Cisplatin in a Patient with Stage IV Anal Cancer
    Nitori, Nobuhiro
    Kato, Yutaro
    Kato, Ayu
    Deguchi, Tomoaki
    Okada, Akihiro
    Kojima, Masayuki
    Kuroda, Junko
    Kadomura, Tomohisa
    Kubota, Keisuke
    Origuchi, Nobuto
    Fujisaki, Masato
    Kitajima, Masaki
    ANTICANCER RESEARCH, 2011, 31 (11) : 3983 - 3989
  • [28] Combined chemotherapy of intravenous and intraperitoneal paclitaxel with S-1 for malignant ascites due to advanced gastric cancer with peritoneal dissemination
    Kitayama, J.
    Ishigami, H.
    Kaisaki, S.
    Hidemura, A.
    Kato, M.
    Nagawa, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer
    Oshima, Takashi
    Yamada, Roppei
    Hatori, Shinsuke
    Kunisaki, Chikara
    Imada, Toshio
    ONCOLOGY REPORTS, 2006, 16 (02) : 361 - 366
  • [30] A phase I study of S-1 and low dose cisplatin for patients with recurrent or advanced gastric cancer
    Shimoyama, S
    Kaminishi, M
    Hiki, N
    Shimizu, N
    Yamaguchi, H
    Mafune, KI
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 353S - 353S